Cargando…

Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)

INTRODUCTION: Whereas interpatient heterogeneity in clinical characteristics and treatment outcomes of NSCLC harboring a KRAS mutation is recognized, the characterization of these patients in Asia has been limited. METHODS: A multicenter, retrospective cohort study was conducted in eight academic ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jiyun, Tan, Aaron C., Zhou, Siqin, Yoon, Shinkyo, Liu, Siyang, Masuda, Ken, Hayashi, Hidetoshi, Batra, Ullas, Kim, Dong-Wan, Goto, Yasushi, Tan, Sze Huey, Wu, Yi-Long, Lee, Dae Ho, Tan, Daniel S.W., Ahn, Myung-Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728099/ https://www.ncbi.nlm.nih.gov/pubmed/35024639 http://dx.doi.org/10.1016/j.jtocrr.2021.100261

Ejemplares similares

KRAS in NSCLC: State of the Art and Future Perspectives
por: Cascetta, Priscilla, et al.
Publicado: (2022)

Unusual Resistance Mechanisms in a Case of ROS1-Rearranged NSCLC: A Case Report
por: Batra, Ullas, et al.
Publicado: (2022)

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
por: Lai, Gillianne G.Y., et al.
Publicado: (2022)

KRAS mutated Non‐Small Lung Carcinoma: A Real World Context from the Indian subcontinent
por: Batra, Ullas, et al.
Publicado: (2022)

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
por: Garrido, Pilar, et al.
Publicado: (2017)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
por: Weidhaas, Joanne B., et al.
Publicado: (2023)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

CCM 87-005
por: Cuperus, J
Publicado: (1987)

DSC 89-005
Publicado: (1989)

BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
por: Jauset, Toni, et al.
Publicado: (2018)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia
por: How, Soon Hin, et al.
Publicado: (2022)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022)

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
por: Brazel, Danielle, et al.
Publicado: (2022)

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2023)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

Generation of three human induced pluripotent stem cell sublines (UCLAi005-A, UCLAi005-B and UCLAi005-C) for reproductive science research
por: Pandolfi, Erica C., et al.
Publicado: (2021)

Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models
por: Haley, John A., et al.
Publicado: (2014)

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
por: Arbour, Kathryn C., et al.
Publicado: (2021)

Asia-Pacific consensus on physical activity and exercise in pregnancy and the postpartum period
por: Lee, Ryan, et al.
Publicado: (2021)

Science Star over Asia
por: Tan, Chris Y. H
Publicado: (2005)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

Exploring MRI based radiomics analysis of intratumoral spatial heterogeneity in locally advanced nasopharyngeal carcinoma treated with intensity modulated radiotherapy
por: Akram, Farhan, et al.
Publicado: (2020)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
por: Noordhof, Anneloes L., et al.
Publicado: (2023)

Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo
por: Brunelli, Laura, et al.
Publicado: (2016)

Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells
por: Chen, Shu-Chen, et al.
Publicado: (2020)

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021)

KRAS oncogene may be another target conquered in non‐small cell lung cancer (NSCLC)
por: Chen, Hanxiao, et al.
Publicado: (2020)

Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
por: Jacobs, Francesca, et al.
Publicado: (2021)

The current landscape of using direct inhibitors to target KRAS(G12C)-mutated NSCLC
por: Batrash, Firas, et al.
Publicado: (2023)

Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy
por: Dai, Xin, et al.
Publicado: (2015)

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
por: Hayashi, Hidetoshi, et al.
Publicado: (2023)

Cutaneous metastases as a presenting sign of metastatic NSCLC
por: McSweeney, William T, et al.
Publicado: (2019)

Complete Genome Sequence of the Carotenoid-Producing Deinococcus sp. Strain AJ005
por: Choi, Jun Young, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mej6mh218c3edf6c64r1ktbao5